AiCure Stock

AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress.

Sign up today and learn more about AiCure Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About AiCure Stock

AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress. IMA provides visual dose confirmation, interactive patient support and engagement, and visual diagnostic capabilities. The platform has been validated to improve patient behavior in randomized controlled trials. In clinical research, AiCure is increasing the probability of trial success and introducing more objective clinical endpoints. In population health, AiCure is enabling intelligent decision-making and improving health outcomes. By 2020, there will be a one million nurse shortage in the US. AiCure is striving to help fill this gap. In clinical research, approximately one quarter of clinical trials fail due to a lack of patient oversight, contributing to over $40 billion in annual losses. AiCure is seeking to accelerate better medications into the market.

Funding History

January 2016$12.3M
November 2017$15.0M

Management

Chief Product Officer

Michelle Marlborough

Co-Founder & CSO

Laura Shafner

Co-Founder & CEO

Adam Hanina

Press

strictlyvc - Jan, 18 2016

StrictlyVC: January 12, 2016

pehub - Jan, 13 2016

AiCure raises $12.25 mln

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo